Liminatus Pharma, Inc. appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 16, 2026, Liminatus Pharma, Inc. (the “Company”) appointed Eric Sunghee Kang as Chief Corporate Strategist of the Company, effective immediately. In this role, Mr. Kang will report to Chris Kim, the Company’s Chief Executive Officer, and will a

